CSIMarket Company Name, Ticker, Suppliers, else..
 
Scholar Rock Holding Corp  (NASDAQ: SRRK)
 
Price: $50.0000 $-1.85 -3.568%
Day's High: $51.1067008972168 Week Perf: -8.46 %
Day's Low: $ 46.54 30 Day Perf: -4.8 %
Volume (M): 5,213,138 52 Wk High: $ 61.76
Volume (M$): $ 0 52 Wk Avg: $45.22
Open: $50.78 52 Wk Low: $27.07



 Market Capitalization (Millions $) 6,531
 Shares Outstanding (Millions) 131
 Employees 289
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -409
 Cash Flow (TTM) (Millions $) 293
 Capital Exp. (TTM) (Millions $) 0

Business Description


Scholar Rock Holding Corp is a clinical-stage biopharmaceutical company that focuses on developing innovative medicines to treat serious diseases in a variety of therapeutic areas. The company's platform is based on targeting the TGF-beta superfamily of proteins, which play a crucial role in regulating cellular processes. Scholar Rock is dedicated to discovering and developing potential therapies that can modulate the TGF-beta superfamily in order to address significant unmet medical needs. The company's pipeline consists of various drug candidates that are undergoing clinical trials for conditions such as fibrosis, immuno-oncology, and musculoskeletal disorders.


   Company Address: 301 Binney Street, 3rd Floor Cambridge 2142 MA
   Company Phone Number: 259 3860   Stock Exchange / Ticker: NASDAQ SRRK


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AGEN   -3.63%    
AMGN   -4.46%    
CHRS   -2.92%    
GILD   -0.23%    
HALO   -1.9%    
IOVA        7.59% 
• View Complete Report
   



Business Update

Scholar Rocks Transformative Year Pioneering Advances in Spinal Muscular Atrophy and Cardiometabolic Therapies

Published Thu, Feb 27 2025 1:33 PM UTC

2024 has proven to be a landmark year for Scholar Rock, a biopharmaceutical company focused on developing innovative treatments for serious diseases like spinal muscular atrophy (SMA) and cardiometabolic disorders. Scholar Rock s recent announcements highlight the impactful progress made in developing treatments targeting protein growth factors, a promising approach that pos...
Business Update

Pioneering Advances in SMA Treatment Scholar Rock to Unveil Phase 3 SAPPHIRE Trial Data at the 2025 MDA Conference,...

Published Fri, Feb 21 2025 2:23 PM UTC

: Scholar Rock, a biopharmaceutical company focused on pioneering therapies for spinal muscular atrophy (SMA) and other serious conditions, is set to present additional clinical data from its Phase 3 SAPPHIRE trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. This article delves into the implications of these forthcoming results for the...
Business Update

Scholar Rock Reports Promising Preclinical Findings for SRK-439 Lean Mass Gains and Fat Loss Enhanced by Metformin

Published Mon, Nov 4 2024 2:36 PM UTC

: Scholar Rock Holding Corp announces new preclinical data for its investigational therapeutic candidate SRK-439, demonstrating a significant increase in lean mass and a greater reduction in fat mass when used in conjunction with metformin. This study presents insights into the potential of SRK-439, further solidifying Scholar Rock’s performance in the market compared to...
Business Update

Scholar Rock Hosts Upcoming Conference Call Amid Financial Challenges and Gradual Progress in ROI

Published Fri, Nov 1 2024 2:12 PM UTC

On November 12, 2024, Scholar Rock Holding Corp is set to host a conference call to discuss its financial results for the third quarter of 2024, alongside an important business update. The call comes against a backdrop of significant financial losses, as the company reported a cumulative net loss of $204 million in the twelve months ending in the second quarter of 2024. This...
Business Update

Scholar Rocks Apitegromab Demonstrates Promising Phase 3 Results in SMA Patients; Announces Strategic Employee Induc...

Published Mon, Oct 7 2024 11:47 AM UTC

Scholar Rock, a biopharmaceutical company listed on NASDAQ as SRRK, has reported significant progress in its development of apitegromab, a pioneering therapy for spinal muscular atrophy (SMA). The company announced that their Phase 3 SAPPHIRE clinical trial (NCT05156320) has successfully met its primary endpoint, showing promising efficacy and safety for the treatment of SMA...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 25.73
PEG (TTM) -

Financial Strength Current
Quick Ratio 6.81
Working Capital Ratio 7.07
Leverage Ratio (MRQ) 1.06
Total Debt to Equity 0.77
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.36 $
Revenues (TTM) -
Cash Flow (TTM) 2.25 $
Cash 3.77 $
Book Value 1.94 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,413,810
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.